Live
Stempeutics Research has got the limited approval from the national drug regulator, DCGI, for its stem cell based product Stempeucel to treat Buerger’s Disease.
Cipla, that has investments in Stempeutics, said in a statement that “The Drugs Controller General (India) has granted limited approval for manufacturing & marketing of stem cell based biological product Stempeucel for the treatment of Buerger’s Disease.”
B N Manohar, Stempeutics CEO has said that “Obtaining DCGI approval for Stempeucel is an important and historic milestone for Stempeutics. We are the first company in India to achieve such approval.”
